Growth & profitability
- Revenue has declined 61.2% per year over the past 5 years.
- Operating margin has contracted, at -123601.7% in the latest year.
Financial health
- Total debt has grown faster than revenue (20.8% vs -61.2% per year).
AVTX Financials Avalo Therapeutics, Inc.
13 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $59000 | -$78M | 0.0% | -123601.7% | — | — | $16M |
| 2024 | $441000 | -$35M | 0.0% | -15535.6% | — | — | $135M |
| 2023 | $2M | -$32M | 33.3% | -1421.6% | — | — | $7M |
| 2022 | $18M | -$42M | 81.0% | -207.4% | -$27M | — | $13M |
| 2021 | $5M | -$84M | 72.4% | -1521.6% | -$71M | — | $55M |
| 2020 | $7M | -$64M | 95.5% | -1087.4% | -$41M | — | $19M |
| 2019 | $7M | -$16M | 108.4% | -239.1% | -$19M | — | $4M |
| 2018 | $7M | -$40M | 53.6% | -503.4% | -$4M | $15M | $11M |
| 2017 | $28M | $12M | 97.7% | 49.9% | $13M | $0 | $2M |
| 2016 | — | -$16M | — | — | -$15M | $2M | $5M |
| 2015 | — | -$10M | — | — | -$10M | $6M | $21M |
| 2014 | — | -$16M | — | — | — | $7M | $12M |
| 2013 | — | -$13M | — | — | — | — | $3M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$20M | — | — | — | — | $25M |
| Dec '25 | $59000 | -$14M | 0.0% | -33461.0% | — | — | $16M |
| Sep '25 | $0 | -$31M | — | — | — | — | $27M |
| Jun '25 | — | -$21M | — | — | — | — | $42M |
| Mar '25 | — | -$13M | — | — | — | — | $125M |
| Dec '24 | $192000 | -$35M | 0.0% | -6932.8% | — | — | $135M |
| Sep '24 | $249000 | $23M | 386.7% | -5165.1% | — | — | $82M |
| Jun '24 | $0 | $98M | — | — | — | — | $93M |
| Mar '24 | $0 | -$121M | — | — | — | — | $110M |
| Dec '23 | $571000 | -$8M | 138.7% | -1341.2% | — | — | $7M |
| Sep '23 | $236000 | -$5M | -4.7% | -1589.0% | — | — | $10M |
| Jun '23 | $643000 | -$8M | -10.1% | -1112.0% | — | — | $6M |
| Mar '23 | $475000 | -$10M | -16.0% | -1850.9% | — | — | $17M |
| Dec '22 | $896000 | -$10M | 30.8% | -988.3% | -$4M | — | $13M |
| Sep '22 | $15M | $3M | 96.5% | 27.4% | $6M | — | $17M |
| Jun '22 | $1M | -$13M | -51.7% | -1145.0% | -$13M | — | $11M |
| Mar '22 | $1M | -$22M | 38.6% | -1777.7% | -$16M | — | $38M |
| Dec '21 | $219000 | -$19M | -93.6% | -8202.3% | -$17M | — | $55M |
| Sep '21 | $1M | -$17M | 32.7% | -1219.5% | -$16M | — | $72M |
| Jun '21 | $3M | -$17M | 97.5% | -510.6% | -$19M | — | $40M |
Valuation over time
How the market has priced AVTX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has risen from 1.3× (Mar '23) to 16037.0× (Jun '26).
P/S
Frequently asked questions
Is AVTX growing its revenue and profit?
Over the past 5 years, Avalo Therapeutics, Inc.'s revenue has declined 61.2% per year. These are computed facts, not advice.
How much debt does AVTX have?
As of FY2025, Avalo Therapeutics, Inc. reported — of total debt against $16M of cash.
What is AVTX's profit margin?
In FY2025, gross margin was —, operating margin -123601.7%, and net margin -132642.4%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.